Skip to Content

NSABP B-55: gBRCA1/2 Mutations and High Risk HER2 Negative

A Randomised, Double-blind, Parallel Group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients With gBRCA1/2 Mutations and High-Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy

Objective

Overview

Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy Experimental: Olaparib Olaparib tablets 300mg b.i.d. p.o. Intervention: Drug: Olaparib Placebo Comparator: Placebo Placebo tablets b.i.d. p.o. Intervention: Drug: Placebo

Key Inclusion Criteria

For a patient to be eligible for participation in this study, all of the following criteria must apply.
  • Histologically confirmed non-metastatic primary invasive adenocarcinoma of the breast that is one of the following phenotypes:

    1. Triple negative breast cancer defined as: ER and PgR negative AND HER2 negative (not eligible for anti-HER2 therapy)
    2. ER and/or PgR positive, HER2 negative
  • Documented germline mutation in BRCA1 or BRCA2 that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function).
  • Completed adequate breast and axilla surgery.
  • Completed at least 6 cycles neoadjuvant or adjuvant chemotherapy containing anthracyclines, taxanes or the combination of both. Prior platinum as potentially curative treatment for prior cancer (e.g. ovarian) or as adjuvant or neoadjuvant treatment for breast cancer is allowed.
  • ECOG 0-1.

Key Exclusion Criteria

A patient will not be eligible for participation in this study if any of the following criteria apply.
  • Any previous treatment with a PARP inhibitor, including olaparib and/or known hypersensitivity to any of the excipients of study treatment.
  • Patients with second primary malignancy. EXCEPTIONS are:

    1. adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, Ductal Carcinoma in situ (DCIS) of the breast, stage 1 grade 1 endometrial carcinoma
    2. other solid tumors and lymphomas (without bone marrow involvement) diagnosed ≥ 5 years prior to randomisation and treated with no evidence of disease recurrence and for whom no more than one line of chemotherapy was applied.
  • Concomitant use of known strong CYP3A inhibitors (e.g., itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (e.g., ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to starting study treatment is 2 weeks. Concomitant use of known strong (e.g., phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or moderate CYP3A inducers (e.g., bosentan, efavirenz, modafinil). The required washout period prior to starting study treatment is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents.
  • Evidence of metastatic breast cancer

Phase: III

Learn More

ClinicalTrials.Gov

IRB Protocol Number
NSABP B-55
Principal Investigator(s)
Dr. Steven Corso, M.D.

Clinical Trial Categories

  • Breast Cancer
Sponsor(s)
AstraZeneca
How to Participate

Kathy Queen, RN
864-560-1044
kqueen@gibbscc.org

Was this page helpful?

Yes
No

Thank you for your feedback!

Thank you for your feedback and helping us to improve our website.
There will be no additional response.

Upcoming Events

News & Highlights

Stay Connected!

Get the latest news on the health topics that matter most to you.

Sign up